A detailed history of Clearstead Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Clearstead Advisors, LLC holds 3,556 shares of VRTX stock, worth $1.45 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
3,556
Previous 3,555 0.03%
Holding current value
$1.45 Million
Previous $1.67 Million 0.78%
% of portfolio
0.03%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$460.0 - $505.78 $460 - $505
1 Added 0.03%
3,556 $1.65 Million
Q2 2024

Aug 09, 2024

BUY
$392.81 - $485.53 $1.15 Million - $1.42 Million
2,928 Added 466.99%
3,555 $1.67 Million
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $59,522 - $65,127
146 Added 30.35%
627 $262,000
Q4 2023

Feb 12, 2024

BUY
$343.0 - $410.68 $66,885 - $80,082
195 Added 68.18%
481 $195,000
Q3 2023

Nov 07, 2023

BUY
$338.18 - $362.46 $7,101 - $7,611
21 Added 7.92%
286 $99,000
Q2 2023

Aug 07, 2023

SELL
$314.42 - $351.91 $1,886 - $2,111
-6 Reduced 2.21%
265 $93,000
Q1 2023

May 09, 2023

SELL
$283.23 - $323.1 $61,744 - $70,435
-218 Reduced 44.58%
271 $85,000
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $132,807 - $148,182
485 Added 12125.0%
489 $142,000
Q1 2022

May 04, 2022

BUY
$221.42 - $260.97 $885 - $1,043
4 New
4 $1,000
Q2 2021

Aug 12, 2021

SELL
$187.49 - $221.1 $29,623 - $34,933
-158 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$207.02 - $241.31 $32,709 - $38,126
158 New
158 $34,000
Q2 2020

Aug 11, 2020

SELL
$225.48 - $295.8 $4,509 - $5,916
-20 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$199.77 - $247.81 $3,995 - $4,956
20 New
20 $5,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Clearstead Advisors, LLC Portfolio

Follow Clearstead Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clearstead Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clearstead Advisors, LLC with notifications on news.